Sign In
Buy TGTX
$40.11
+3.47 (+9.47%)
At Close: Jun 03, 2026
TG Therapeutics: Bright Outlook, Bolstered By Briumvi And Upcoming Trials
02:04pm, Friday, 14'th Mar 2025
TG Therapeutics is rated a strong buy with a 12-month price target of $44, driven by positive Briumvi sales and future trial plans. Briumvi exceeded FY 2024 sales forecasts and is expected to surpass
TG Therapeutics: Exciting Briumvi Performance, Looking To Re-Enter
04:11pm, Wednesday, 12'th Mar 2025
TGTX's Briumvi, despite initial struggles, has shown strong performance by consistently beating earnings estimates, even with competition from Roche's Zunovo. Briumvi's competitive advantages include
S&P 500 Pair, Warren Buffet Pick Lead Five Stocks Near Buy Points Amid Market Shakeout
12:05pm, Saturday, 08'th Mar 2025
These watch list stocks have beenholding near buy points while the market has been breaking down. The post S&P 500 Pair, Warren Buffet Pick Lead Five Stocks Near Buy Points Amid Market Shakeout appear
Why TG Therapeutics Stock Was Soaring This Week
05:23pm, Friday, 07'th Mar 2025
Following news of an estimates-topping fourth quarter, TG Therapeutics (TGTX 9.24%) stock was a hot item with investors over the past few days. According to data compiled by S&P Global Market Intellig
NEW YORK, March 07, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the upcoming schedule of presentations highlighting BRIUMVI® (ublituximab-xiiy) data in patients wit
Privia Health, Corcept and three other low-key but high-earnings growth potential stocks to invest in 2025
07:03am, Tuesday, 04'th Mar 2025
With the broader market facing volatility, a clutch of experts are recommending investors to look beyond mega-cap stocks like Meta, Amazon, and Netflix for opportunities in stocks with strong earnings
TG Therapeutics: A Wonderful Hold
03:59pm, Monday, 03'rd Mar 2025
TG Therapeutics, Inc. stock is surging due to strong financial performance and a promising outlook, driven by the success of its flagship drug, Briumvi. Revenue for Q4 reached $107.3 million, up 146%
TG Therapeutics, Inc. (TGTX) Q4 2024 Earnings Call Transcript
11:55am, Monday, 03'rd Mar 2025
TG Therapeutics, Inc. (NASDAQ:TGTX ) Q4 2024 Earnings Conference Call March 3, 2025 8:30 AM ET Company Participants Jenna Bosco - Senior Vice President of Corporate Communications Michael Weiss - Chai
TG Therapeutics, A New Leaderboard Stock, Skyrockets 17% On Sales Beat, Bullish Guide
11:48am, Monday, 03'rd Mar 2025
TG Therapeutics stock skyrocketed Monday after easily beating fourth-quarter sales expectations and issuing a bullish outlook for 2025. The post TG Therapeutics, A New Leaderboard Stock, Skyrockets 17
NEW YORK, Feb. 27, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the presentation of data from the ULTIMATE I & II Phase 3 trials and the ENHANCE Phase 3b trial evalua
TG Therapeutics to Host Conference Call on Fourth Quarter and Full Year 2024 Financial Results and Business Update
07:30am, Wednesday, 26'th Feb 2025
NEW YORK, Feb. 26, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that a conference call will be held, Monday, March 3, 2025, at 8:30 AM ET to discuss results for the f
All You Need to Know About TG Therapeutics (TGTX) Rating Upgrade to Buy
01:00pm, Monday, 27'th Jan 2025
TG Therapeutics (TGTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
TG Therapeutics: Entering 2025 With Increased Investor Expectations
02:48pm, Thursday, 23'rd Jan 2025
TG Therapeutics presented at the JP Morgan Healthcare conference this month and CEO Weiss provided commercial and pipeline updates. Briumvi's strong Q4 2024 performance, with $103.6 million in net sal
TG Therapeutics: 2025 Revenues Will Smash Expectations
02:17am, Tuesday, 21'st Jan 2025
TG Therapeutics exceeded 2024 revenue guidance by 24%, signaling strong growth and market share capture with its Multiple Sclerosis treatment, Briumvi. 2025 revenue guidance of $540 million implies sl
TGTX Announces 2024 Preliminary Results, 2025 Goals, Shares Rise
10:10am, Wednesday, 15'th Jan 2025
TG Therapeutics reports preliminary fourth-quarter and full-year 2024 product revenues. It also provides revenue guidance for 2025 and other pipeline goals.
